Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.01
$0.00
$0.00
$0.05
$663K1.892,978 shs40 shs
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$1.72
-1.7%
$2.33
$1.52
$13.20
$2.27M0.54129,021 shs10,925 shs
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$0.22
$0.22
$0.17
$0.40
$6.47M0.521,980 shsN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
$2.02
+8.6%
$13.23
$4.50
$27.32
$2.90M2.0778,851 shs313,628 shs
Praxsyn Co. stock logo
PXYN
Praxsyn
$0.00
$0.00
$0.01
$85K-1.01N/AN/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%+257.14%+185.71%+809.09%-80.00%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-1.69%+10.76%-20.02%-17.84%-82.08%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
0.00%0.00%-6.36%-12.96%-40.61%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
+8.60%+19.53%+0.50%+16.09%-23.77%
Praxsyn Co. stock logo
PXYN
Praxsyn
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.3357 of 5 stars
3.35.00.00.00.00.00.6
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.50
Moderate Buy$21.001,120.93% Upside
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$1.56M0.43N/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$420K5.41N/AN/A$0.57 per share3.02
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$50.67M0.13$0.04 per share5.75$0.63 per share0.34
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A$13.13 per shareN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
-$880KN/A0.00N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
-$30K-$0.01N/AN/A-0.76%-2.05%-1.47%5/6/2024 (Estimated)
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest NVUS, ACUR, INBP, PXYN, and CYCC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/19/2024Q4 2023
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$6.35-$6.23+$0.12-$6.23N/A$0.03 million
2/12/2024Q2 2024
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.01-$0.01-$0.01N/A$11.51 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/A
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
0.91
0.91
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A
2.93
0.84
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
18.78
18.78
Praxsyn Co. stock logo
PXYN
Praxsyn
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
966.35 million52.95 millionNot Optionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2,0181.32 million1.21 millionOptionable
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
14130.10 million16.37 millionNot Optionable
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
71.44 millionN/ANot Optionable
Praxsyn Co. stock logo
PXYN
Praxsyn
66847.94 millionN/ANot Optionable

NVUS, ACUR, INBP, PXYN, and CYCC Headlines

SourceHeadline
PXYN.PK - Praxsyn Corp | Stock Price & Latest News | ReutersPXYN.PK - Praxsyn Corp | Stock Price & Latest News | Reuters
reuters.com - August 13 at 8:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acura Pharmaceuticals logo

Acura Pharmaceuticals

OTCMKTS:ACUR
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Cyclacel Pharmaceuticals logo

Cyclacel Pharmaceuticals

NASDAQ:CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Integrated BioPharma logo

Integrated BioPharma

OTCMKTS:INBP
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Novus Therapeutics logo

Novus Therapeutics

NASDAQ:NVUS
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Praxsyn logo

Praxsyn

OTCMKTS:PXYN
Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.